The judge overseeing product liability litigation against AstraZeneca's blockbuster Seroquel will not consider calls to dismiss certain strict liability claims from the consolidated cases until the pharmaceutical giant offers up a detailed argument.
Northwest Biotherapeutics, which saw its share price more than double after the biotechnology company announced approval of the world’s first brain cancer vaccine, faces two purported securities class actions for allegedly deceiving investors with misleading statements.
Marking the latest development in Boston Scientific Corp.'s patent infringement feud with ev3 Inc. over embolic protection devices, a federal judge has agreed with a magistrate judge's recommendation that the medical device maker's trade secret claim against its rival should be dismissed for lack of subject matter jurisdiction.
A federal court judge has denied Boston Scientific Corp.'s motions to toss a putative class action filed by employees who claim the medical device maker breached its fiduciary duty to administer and watch over their retirement benefits.
What makes a top company pick up the phone and call on the product liability practice group at Nixon Peabody LLP when it's got an important issue to deal with? According to Joseph Ortego, the firm's national practice group leader, the reason is simple: a high success rate at trial.
Yet more plaintiffs have been dismissed from the massive product liability litigation over pharmaceutical giant Pfizer Inc.'s controversial anti-inflammatory drugs Bextra and Celebrex.
Seeking to open another front in the war against Novartis Pharmaceuticals Corp., a second group of plaintiffs has asked to be certified as a class in the Aredia and Zometa product liability litigation. These plaintiffs, who might be at risk, want to be monitored for the jaw deterioration the drugs allegedly cause.
A former Goldman Sachs Group associate has pled guilty to his role in a massive insider trading ring, admitting he traded on tips from a grand juror, two printing plant workers and a former financial analyst who leaked him details on big mergers, including drug giant Novartis AG's takeover of Eon Labs.
Apotex Inc. has asserted that a key declaration by a doctor bolsters its opposition to Allergan Inc.’s bid for summary judgment, which alleges the Canadian generic drug maker infringed a patent for Acular when Apotex submitted an application for a generic copy of the itchy eye treatment.
A federal appeals court panel has, for the most part, upheld a lower court ruling that four Ormco Corp. patents were invalid and therefore not infringed by rival orthodontic maker Align Technology Inc.
Bankrupt breast implant maker MediCor Ltd. has won court approval to sell its assets and the assets of some of its nondebtor subsidiaries.
A new government study will examine whether positive visuals in television drug advertisements interfere with the way viewers process potential side effects.
Celgene Corp. has filed another patent suit against Barr Pharmaceuticals Inc. in an attempt to stave off generic competition for its lucrative cancer treatment Thalomid, which brought in $117.7 million in net sales in the second quarter of 2007.
Despite the protests of Novartis Pharmaceuticals Corp., a federal district judge has granted the request of two plaintiffs to remand their case to state court, sending the suit back to the lower court as the product liability litigation over bone cancer drugs Aredia and Zometa continues to unfold.
Abbott Laboratories Inc. has lashed out at a judge's order allowing a plaintiff in the average wholesale price litigation to share discovery from other state cases against the drug maker with government prosecutors, arguing that the information has “nothing to do with the claims” in the multidistrict action.
A federal bankruptcy judge has given the green light to a buyout deal that will see creditors of Nellson Nutraceutical Inc. shelling out $153.5 million to purchase the embattled diet bar maker's assets.
Bayer AG may soon face regulatory scrutiny over Trasylol, with the U.S. Food and Drug Administration set to hear testimony from a group of outside experts as to whether the blood-clotting drug can cause kidney damage, heart failure and even death.
The Judicial Panel on Multidistrict Litigation has refused a request to centralize three cases filed against Pfizer, Inc. over its birth control product Depo-Provera, handing drug giant Pfizer a victory in the transfer dispute.
MedPointe Healthcare Inc. on Wednesday filed a patent infringement suit against Cobalt Pharmaceuticals Inc. in an attempt to stop the Canadian drug company from making a generic version of its anti-allergy medication.
A federal judge handed a McKesson Corp. unit and Becton, Dickinson and Co. a setback Wednesday in a product liability suit that accuses them of manufacturing and distributing defective syringes.